Tech Company Financing Transactions
MeiraGTx Funding Round
On 7/7/2026, MeiraGTx landed $400 million in financing from Oberland Capital.
Transaction Overview
Company Name
Announced On
7/7/2026
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$400,000,000
Round
Undisclosed
Investors
Oberland Capital (Michael Bloom)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
655 Third Avenue 1115
New York, NY 10017
USA
New York, NY 10017
USA
Phone
Website
Email Address
Overview
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, Parkinson's disease and radiation-induced xerostomia. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexandria Forbes
Chief Medical Officer
Robert Zeldin
Chief Operating Officer
Richard Giroux
Chief Scientific Officer
Stuart Naylor
Vice President
Tassos Georgiadis
Vice President
Tim Randall
Vice President
Christine Sheehy
VP - Bus. Development
Penny Fleck
VP - Bus. Development
David Rubinstein
VP - General Counsel
Robert Wollin
Browse more venture capital transactions:
Prev: 7/7/2026: Stylework venture capital transaction
Next: 7/7/2026: One Raven venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs